Yes, it will do that.
More generally, RR is better than OR whenever its possible to calculate
RR. Before the relogit papers, this wasn't possible in case-control
studies, but was in prospective studies. These papers show how to compute
it in case-control (reptrospective) studies too, and the software will do
either.
Gary
On Thu, 27 Oct 2005, Boye, Mark wrote:
When conducting prospective research, it has been
suggested the RR is a
better estimator than OR (Zou, Am J Epidemiol 2004;159:702-706). Can ReLogit
be adapted to accommodate this specification?
Thank you,
Mark
Mark E. Boye MBA, MPH, Ph.D.
Sr. Outcomes Research Scientist
WW Outcomes Research
Midwest/Ann Arbor Development Site
Pfizer Inc
1600/200/2101
2800 Plymouth Road
Ann Arbor, MI 48105-2430
Tel: 734-622-4856
Fax: 734-622-2055
E-mail: mark.boye(a)pfizer.com
----------------------------------------------------------------------
LEGAL NOTICE
Unless expressly stated otherwise, this message is confidential and may be privileged.
It is intended for the addressee(s) only. Access to this E-mail by anyone else is
unauthorized. If you are not an addressee, any disclosure or copying of the contents of
this E-mail or any action taken (or not taken) in reliance on it is unauthorized and may
be unlawful. If you are not an addressee, please inform the sender immediately.
-
Zelig Mailing List, served by Harvard-MIT Data Center
Send messages: zelig(a)latte.harvard.edu
[un]subscribe Options:
http://lists.hmdc.harvard.edu/?info=zelig
Zelig program information:
http://gking.harvard.edu/zelig/